Shields Carol L, Materin Miguel A, Teixeira Luiz, Mashayekhi Arman, Ganguly Arupa, Shields Jerry A
Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Ophthalmology. 2007 Oct;114(10):1919-24. doi: 10.1016/j.ophtha.2007.04.054. Epub 2007 Aug 15.
To evaluate the presence of chromosome 3 monosomy in small choroidal melanoma using fine-needle aspiration biopsy (FNAB).
Noncomparative case series.
Fifty-six patients with small choroidal melanoma measuring 3 mm or less in thickness who were undergoing plaque radiotherapy.
Fine-needle aspiration biopsy was used at the time of plaque radiotherapy to sample tumor cells using a 27-gauge long needle via an indirect transvitreal approach into the tumor apex for postequatorial tumors or a 30-gauge short needle via a direct transscleral approach into the tumor base for preequatorial tumors.
Chromosome 3 monosomy in small choroidal melanoma.
The median tumor thickness was 2.6 mm. Monosomy 3 was found in 15 (27%) cases and disomy 3 was found in 32 (57%) cases. In 9 (16%) cases, genomic DNA yield was insufficient for genetic analysis. Fine-needle aspiration biopsy with a 27-gauge needle transvitreal approach provided quantity sufficient for genetic testing in 31 (97%) of 32 cases versus 16 (67%) of 24 cases sampled with a 30-gauge transscleral technique. Compared with disomy 3 tumors, monosomy 3 tumors were statistically more likely to occur in older patients (P = 0.040). Monosomy 3 (versus disomy 3) tumors showed thickness of more than 2 mm in 100% (vs. 84%), subretinal fluid in 87% (vs. 94%), symptoms in 40% (vs. 56%), orange pigment in 93% (vs. 81%), and margin of 3 mm or less to the optic disc in 20% (vs. 50%). There was no statistical difference between monosomy 3 and disomy 3 tumors in the presence or number of these clinical factors. However, small choroidal melanomas with monosomy 3 mutation were more likely to have had documented growth (63%) compared with those with disomy 3 (25%; P = 0.025; odds ratio, 5.00).
Using FNAB at the time of plaque radiotherapy, monosomy 3 was found in approximately 27% of small choroidal melanomas, more often in older patients and tumors with documented growth. Transvitreal biopsy into the tumor apex provided better yield compared with transscleral biopsy into the tumor base.
利用细针穿刺活检(FNAB)评估小脉络膜黑色素瘤中3号染色体单体的存在情况。
非对照病例系列。
56例厚度为3毫米或更小的小脉络膜黑色素瘤患者,均接受敷贴放射治疗。
在敷贴放射治疗时使用细针穿刺活检,对于赤道后肿瘤,通过间接经玻璃体途径,使用27号长针穿刺肿瘤顶端以获取肿瘤细胞;对于赤道前肿瘤,通过直接经巩膜途径,使用30号短针穿刺肿瘤底部。
小脉络膜黑色素瘤中的3号染色体单体。
肿瘤厚度中位数为2.6毫米。15例(27%)发现3号染色体单体,32例(57%)发现3号染色体二体。9例(16%)基因组DNA产量不足以进行基因分析。采用27号针经玻璃体途径的细针穿刺活检,32例中有31例(97%)获取的样本量足以进行基因检测,而采用30号经巩膜技术的24例中只有16例(67%)。与3号染色体二体肿瘤相比,3号染色体单体肿瘤在老年患者中更常见(P = 0.040)。3号染色体单体(相对于二体)肿瘤中,100%(相对于84%)厚度超过2毫米,87%(相对于94%)有视网膜下液,40%(相对于56%)有症状,93%(相对于81%)有橙色色素,20%(相对于50%)距视盘边缘3毫米或更小。这些临床因素的存在或数量在3号染色体单体和二体肿瘤之间无统计学差异。然而,与3号染色体二体的小脉络膜黑色素瘤相比,有3号染色体单体突变的小脉络膜黑色素瘤更有可能有生长记录(63% 相对于25%;P = 0.025;优势比,5.00)。
在敷贴放射治疗时使用FNAB,约27%的小脉络膜黑色素瘤中发现3号染色体单体,在老年患者和有生长记录的肿瘤中更常见。与经巩膜穿刺肿瘤底部活检相比,经玻璃体穿刺肿瘤顶端活检的成功率更高。